ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
88.91
-2.32 (-2.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close91.23
Open90.93
Bid88.57 x 900
Ask89.00 x 900
Day's Range88.50 - 91.01
52 Week Range65.63 - 133.74
Volume837,892
Avg. Volume1,154,459
Market Cap2.64B
Beta (3Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-10.86
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est160.60
Trade prices are not sourced from all markets
  • Benzinga14 hours ago

    Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment

    A little more than two months after it reported failed results for a late-stage study dubbed STELLAR-4, Gilead said Thursday that another Phase 3 study dubbed STELLAR-3 that evaluated its selonsertib for patients with bridging fibrosis due to NASH did not meet the pre-specified week 48 primary endpoint. The endpoint was for a histologic improvement in fibrosis of more than one stage without worsening of NASH. NASH has no approved drug treatment and therefore offers huge potential for the first mover.

  • 5 Top Pharmaceutical Stocks to Buy in 2019
    Motley Fool6 days ago

    5 Top Pharmaceutical Stocks to Buy in 2019

    Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool9 days ago

    3 Top Healthcare Stocks to Buy in April

    GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.

  • Gilead to Collaborate with Novo Nordisk for NASH Treatment
    Zacks10 days ago

    Gilead to Collaborate with Novo Nordisk for NASH Treatment

    Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.

  • Why Intercept's Success Was a Big Disappointment
    Motley Fool14 days ago

    Why Intercept's Success Was a Big Disappointment

    The complete presentation of results from the Regenerate trial wasn't exactly what investors were expecting.

  • Why Intercept Pharmaceuticals, Weight Watchers International, and Canopy Growth Slumped Today
    Motley Fool14 days ago

    Why Intercept Pharmaceuticals, Weight Watchers International, and Canopy Growth Slumped Today

    Gloomy views of these businesses sent their stocks lower.

  • Benzinga15 days ago

    Is Intercept Pharma's Updated Late-Stage NASH Data A Sell-The-News Event?

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced additional positive data from its pivotal Phase 3 REGENERATE trial Wednesday. The trial is evaluating Intercept's obeticholic acid, or OCA, in patients with liver fibrosis due to non-alcoholic steatohepatitis, or NASH. The once-daily OCA 25mg dose had met the primary endpoint of fibrosis improvement by one point or greater, with no worsening of NASH in 23.1 percent of patients compared to 11.9 percent of placebo patients at the planned 18-month interim analysis point.

  • Intercept Reports Additional Positive Data From NASH Study
    Zacks15 days ago

    Intercept Reports Additional Positive Data From NASH Study

    Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.

  • Benzinga15 days ago

    The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 10) Fulgent Genetics Inc (NASDAQ: FLGT ) Intuitive Surgical, ...

  • GlobeNewswire15 days ago

    Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional supportive data from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). The new data based on additional analyses show that OCA demonstrated robust efficacy across a range of additional histologic and biochemical parameters. “Halting or reversing fibrosis is a central therapeutic objective for patients with NASH, so the results from the 18-month interim analysis of REGENERATE are highly meaningful and clinically important,” said Zobair M. Younossi, M.D., PhD, Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Professor of Medicine at Virginia Commonwealth University, Inova Campus and the Chair of the REGENERATE Steering Committee.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ICPT are favorable, with net inflows of $2.53 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzinga18 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

    Biotech stocks ended higher for the second straight week, with the presentations at the American Association of Cancer Research annual meeting taking the spotlight. Additionally, there were clinical trial ...

  • GlobeNewswire22 days ago

    Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019

    NEW YORK, April 04, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences
    Motley Fool23 days ago

    Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences

    These two biotechs have been stellar growth vehicles for investors, but only one stock is worth buying right now.

  • Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics
    Zacks24 days ago

    Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics

    Novartis (NVS) is set to acquire IFM Tre, a subsidiary of IFM Therapeutics LLC, and strengthen its pipeline of drugs for chronic inflammatory disorders.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool26 days ago

    3 Top Biotech Stocks to Buy Right Now

    These biotech stocks could have a lot of room to run.

  • 2 Biotechs With Big Dates in April
    Motley Fool27 days ago

    2 Biotechs With Big Dates in April

    Here's what you need to know about two biotechs that will present trial results that could send their stock prices soaring -- or plummeting.

  • How Many Insiders Sold Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares?
    Simply Wall St.27 days ago

    How Many Insiders Sold Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty...

  • Why Is Intercept (ICPT) Up 12.2% Since Last Earnings Report?
    Zacks27 days ago

    Why Is Intercept (ICPT) Up 12.2% Since Last Earnings Report?

    Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
    Zackslast month

    Conatus (CNAT) Declines on Failure of NASH Fibrosis Study

    Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

  • Benzingalast month

    Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

    Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate. What Happened ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ICPT earnings conference call or presentation 28-Feb-19 1:30pm GMT

    Q4 2018 Intercept Pharmaceuticals Inc Earnings Call

  • Why Intercept Pharmaceuticals Stock Hit the Skids in February
    Motley Fool2 months ago

    Why Intercept Pharmaceuticals Stock Hit the Skids in February

    Intercept's NASH data disappointed investors last month.

  • GlobeNewswire2 months ago

    Intercept to Present at Upcoming Investor Conferences

    NEW YORK, March 05, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.